8-K: Genprex Announces Research Collaboration to Study Reqorsa in Combination with ALK-Inhibitors for Lung Cancer

Genprex has entered into a sponsored research agreement with the University of Michigan Rogel Cancer Center to study its lead drug candidate, Reqorsa, in combination with ALK-inhibitors for ALK-positive lung cancer.

Summary

• Genprex has announced a Sponsored Research Agreement (SRA) with the University of Michigan Rogel Cancer Center to investigate the use of Reqorsa, its lead drug candidate, in combination with ALK-inhibitors for ALK-positive lung cancer.
• The research will focus on TUSC2, the tumor suppressor gene used in Reqorsa, and its effectiveness when combined with ALK-inhibitors.
• Genprex is also collaborating with ALK Positive, a non-profit patient-driven research organization, to share the cost of the SRA.
• Preclinical data presented at the April 2024 American Association for Cancer Research Annual Meeting showed that Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines.
• Researchers found that overexpressing TUSC2 using Reqorsa treatment in ALK+ lung cancer cell lines inhibited the ability of the cells to form colonies.
• The study concluded that Reqorsa or a TUSC2-containing plasmid was effective in decreasing cell growth and proliferation through the activation of apoptotic pathways in ALK+ NSCLC cell lines.
• Genprex believes this research suggests that Reqorsa may be an effective treatment in patients progressing on alectinib.

Sentiment

Score: 7

Explanation: The document is positive due to the new research collaboration and promising preclinical data, but it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The collaboration with the University of Michigan Rogel Cancer Center and ALK Positive expands Genprex's research program.
• Preclinical data suggests that Reqorsa may be effective in treating ALK+ lung cancer, including those resistant to alectinib.
• The research could lead to a new therapeutic treatment for patients with ALK+ lung cancer.

Risks

• The success of the research is not guaranteed, and actual results may differ from expectations.
• Genprex's ability to advance the clinical development, manufacturing, and commercialization of its product candidates is subject to risks and uncertainties.
• The timing and success of Genprex's clinical trials and regulatory approvals are uncertain.
• Genprex's ability to maintain compliance with Nasdaq listing requirements and obtain capital to meet its long-term liquidity needs is not guaranteed.

Future Outlook

Genprex is exploring the potential of Reqorsa in combination with ALK-inhibitors as a therapeutic treatment for ALK-positive lung cancer and plans to continue advancing its clinical development programs.

Management Comments

• Genprex believes this research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.

Industry Context

This announcement is relevant to the oncology and gene therapy sectors, particularly in the area of targeted therapies for lung cancer. The collaboration with a major cancer center and a patient advocacy group highlights the growing trend of partnerships in drug development.

Comparison to Industry Standards

• The use of TUSC2 as a tumor suppressor gene in gene therapy is a novel approach, but it is being explored by other companies in the oncology space.
• The combination of gene therapy with ALK-inhibitors is a relatively new area of research, and Genprex's work is at the forefront of this field.
• Other companies such as Pfizer with Lorbrena and Roche with Alecensa are also developing ALK inhibitors, but Genprex's approach is unique in combining it with gene therapy.

Stakeholder Impact

• Shareholders may view this announcement positively due to the potential for new therapeutic treatments.
• Patients with ALK-positive lung cancer may benefit from the research if it leads to new treatment options.
• Employees of Genprex may be impacted by the progress of the research and development programs.

Next Steps

• Genprex will continue to work with the University of Michigan Rogel Cancer Center and ALK Positive on the sponsored research agreement.
• Further clinical studies of REQORSA as an anti-ALK NSCLC treatment strategy are expected.

Key Dates

Keywords

Reqorsa, TUSC2, ALK-inhibitors, lung cancer, ALK-positive, gene therapy, cancer research, apoptosis, non-small cell lung cancer, clinical trials